APO Research
Talk to an analyst

APO RESEARCH · REPORT

Complement Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Complement Inhibitors Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchComplement Inhibitors Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement Inhibitors Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Complement Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement Inhibitors Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement Inhibitors Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Complement Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Complement Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Complement Inhibitors market include Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas Pharma, CSL Behring, Pharming Healthcare, Regeneron Pharmaceuticals, Samsung Bioepis and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Complement Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Complement Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Complement Inhibitors Segment by Company

Alexion Pharmaceuticals

Amgen

Apellis Pharmaceuticals

Astellas Pharma

CSL Behring

Pharming Healthcare

Regeneron Pharmaceuticals

Samsung Bioepis

UCB

Roche

Novartis

Sanofi

Takeda

Complement Inhibitors Segment by Type

Complement Factor D Inhibitor

Complement Factor B Inhibitor

Complement C5 Inhibitors

Complement C3 Inhibitors

C1 Esterase Inhibitors

Complement Inhibitors Segment by Application

Geographic Atrophy (GA)

Atypical Hemolytic Uremic Syndrome (aHUS)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Others

Complement Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Complement Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Complement Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Complement Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Complement Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Complement Inhibitors industry.

Chapter 3: Detailed analysis of Complement Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Complement Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Complement Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Complement Inhibitors Industry Trends Table 2. Complement Inhibitors Industry Drivers Table 3. Complement Inhibitors Industry Opportunities and Challenges Table 4. Complement Inhibitors Industry Restraints Table 5. Global Complement Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Complement Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Complement Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Complement Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Complement Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Complement Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Complement Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Complement Inhibitors Company, Product Type & Application Table 13. Global Complement Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Complement Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Complement Factor D Inhibitor Table 18. Significant Companies of Complement Factor B Inhibitor Table 19. Significant Companies of Complement C5 Inhibitors Table 20. Significant Companies of Complement C3 Inhibitors Table 21. Significant Companies of C1 Esterase Inhibitors Table 22. Global Complement Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Complement Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Complement Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Complement Inhibitors Sales Volume Share by Type (2021-2026) Table 26. Global Complement Inhibitors Sales Volume Share by Type (2027-2032) Table 27. Global Complement Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Complement Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Complement Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Complement Inhibitors Sales Value Share by Type (2021-2026) Table 31. Global Complement Inhibitors Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Geographic Atrophy (GA) Table 33. Significant Companies of Atypical Hemolytic Uremic Syndrome (aHUS) Table 34. Significant Companies of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 35. Significant Companies of Others Table 36. Global Complement Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Complement Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Complement Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Complement Inhibitors Sales Volume Share by Application (2021-2026) Table 40. Global Complement Inhibitors Sales Volume Share by Application (2027-2032) Table 41. Global Complement Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Complement Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Complement Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Complement Inhibitors Sales Value Share by Application (2021-2026) Table 45. Global Complement Inhibitors Sales Value Share by Application (2027-2032) Table 46. Global Complement Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Complement Inhibitors Sales by Region (2021-2026) & (K Units) Table 48. Global Complement Inhibitors Sales Market Share by Region (2021-2026) Table 49. Global Complement Inhibitors Sales by Region (2027-2032) & (K Units) Table 50. Global Complement Inhibitors Sales Market Share by Region (2027-2032) Table 51. Global Complement Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Complement Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Complement Inhibitors Sales Value Share by Region (2021-2026) Table 54. Global Complement Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Complement Inhibitors Sales Value Share by Region (2027-2032) Table 56. Global Complement Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Complement Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Complement Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Complement Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Complement Inhibitors Sales by Country (2021-2026) & (K Units) Table 61. Global Complement Inhibitors Sales Market Share by Country (2021-2026) Table 62. Global Complement Inhibitors Sales by Country (2027-2032) & (K Units) Table 63. Global Complement Inhibitors Sales Market Share by Country (2027-2032) Table 64. Global Complement Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Complement Inhibitors Sales Value Market Share by Country (2021-2026) Table 66. Global Complement Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Complement Inhibitors Sales Value Market Share by Country (2027-2032) Table 68. Alexion Pharmaceuticals Company Information Table 69. Alexion Pharmaceuticals Business Overview Table 70. Alexion Pharmaceuticals Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Alexion Pharmaceuticals Complement Inhibitors Product Portfolio Table 72. Alexion Pharmaceuticals Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Amgen Complement Inhibitors Product Portfolio Table 77. Amgen Recent Development Table 78. Apellis Pharmaceuticals Company Information Table 79. Apellis Pharmaceuticals Business Overview Table 80. Apellis Pharmaceuticals Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Apellis Pharmaceuticals Complement Inhibitors Product Portfolio Table 82. Apellis Pharmaceuticals Recent Development Table 83. Astellas Pharma Company Information Table 84. Astellas Pharma Business Overview Table 85. Astellas Pharma Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Astellas Pharma Complement Inhibitors Product Portfolio Table 87. Astellas Pharma Recent Development Table 88. CSL Behring Company Information Table 89. CSL Behring Business Overview Table 90. CSL Behring Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. CSL Behring Complement Inhibitors Product Portfolio Table 92. CSL Behring Recent Development Table 93. Pharming Healthcare Company Information Table 94. Pharming Healthcare Business Overview Table 95. Pharming Healthcare Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pharming Healthcare Complement Inhibitors Product Portfolio Table 97. Pharming Healthcare Recent Development Table 98. Regeneron Pharmaceuticals Company Information Table 99. Regeneron Pharmaceuticals Business Overview Table 100. Regeneron Pharmaceuticals Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Regeneron Pharmaceuticals Complement Inhibitors Product Portfolio Table 102. Regeneron Pharmaceuticals Recent Development Table 103. Samsung Bioepis Company Information Table 104. Samsung Bioepis Business Overview Table 105. Samsung Bioepis Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Samsung Bioepis Complement Inhibitors Product Portfolio Table 107. Samsung Bioepis Recent Development Table 108. UCB Company Information Table 109. UCB Business Overview Table 110. UCB Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. UCB Complement Inhibitors Product Portfolio Table 112. UCB Recent Development Table 113. Roche Company Information Table 114. Roche Business Overview Table 115. Roche Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Roche Complement Inhibitors Product Portfolio Table 117. Roche Recent Development Table 118. Novartis Company Information Table 119. Novartis Business Overview Table 120. Novartis Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Novartis Complement Inhibitors Product Portfolio Table 122. Novartis Recent Development Table 123. Sanofi Company Information Table 124. Sanofi Business Overview Table 125. Sanofi Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Sanofi Complement Inhibitors Product Portfolio Table 127. Sanofi Recent Development Table 128. Takeda Company Information Table 129. Takeda Business Overview Table 130. Takeda Complement Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Takeda Complement Inhibitors Product Portfolio Table 132. Takeda Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Complement Inhibitors Distributors List Table 136. Complement Inhibitors Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Complement Inhibitors Product Image Figure 2. Global Complement Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Complement Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Complement Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Complement Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Complement Factor D Inhibitor Image Figure 10. Complement Factor B Inhibitor Image Figure 11. Complement C5 Inhibitors Image Figure 12. Complement C3 Inhibitors Image Figure 13. C1 Esterase Inhibitors Image Figure 14. Global Complement Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Complement Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Complement Inhibitors Sales Volume Share by Type (2021-2032) Figure 17. Global Complement Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Complement Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Complement Inhibitors Sales Value Share by Type (2021-2032) Figure 20. Geographic Atrophy (GA) Image Figure 21. Atypical Hemolytic Uremic Syndrome (aHUS) Image Figure 22. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 23. Others Image Figure 24. Global Complement Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Complement Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Complement Inhibitors Sales Volume Share by Application (2021-2032) Figure 27. Global Complement Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Complement Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Complement Inhibitors Sales Value Share by Application (2021-2032) Figure 30. Global Complement Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Complement Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Complement Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Complement Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. North America Complement Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Complement Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Complement Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. South America Complement Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Complement Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Complement Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Complement Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Complement Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Complement Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Complement Inhibitors Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Complement Inhibitors Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Complement Factor D Inhibitor
  • Complement Factor B Inhibitor
  • Complement C5 Inhibitors
  • Complement C3 Inhibitors
  • C1 Esterase Inhibitors
Applications
  • Geographic Atrophy (GA)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Others
Companies covered
  • Alexion Pharmaceuticals
  • Amgen
  • Apellis Pharmaceuticals
  • Astellas Pharma
  • CSL Behring
  • Pharming Healthcare
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • UCB
  • Roche
  • Novartis
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Complement Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Complement Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Complement Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Complement Inhibitors Market Dynamics
  1. 2.1 Complement Inhibitors Industry Trends
  2. 2.2 Complement Inhibitors Industry Drivers
  3. 2.3 Complement Inhibitors Industry Opportunities and Challenges
  4. 2.4 Complement Inhibitors Industry Restraints
3 Complement Inhibitors Market by Company
  1. 3.1 Global Complement Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Complement Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Complement Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Complement Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Complement Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Complement Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Complement Inhibitors Company Product Type and Application
  8. 3.8 Global Complement Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Complement Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Complement Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Complement Inhibitors Market by Type
  1. 4.1 Complement Inhibitors Type Introduction
  2. 4.1.1 Complement Factor D Inhibitor
  3. 4.1.2 Complement Factor B Inhibitor
  4. 4.1.3 Complement C5 Inhibitors
  5. 4.1.4 Complement C3 Inhibitors
  6. 4.1.5 C1 Esterase Inhibitors
  7. 4.2 Global Complement Inhibitors Sales Volume by Type
  8. 4.2.1 Global Complement Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Complement Inhibitors Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Complement Inhibitors Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Complement Inhibitors Sales Value by Type
  12. 4.3.1 Global Complement Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Complement Inhibitors Sales Value by Type (2021-2032)
  14. 4.3.3 Global Complement Inhibitors Sales Value Share by Type (2021-2032)
5 Complement Inhibitors Market by Application
  1. 5.1 Complement Inhibitors Application Introduction
  2. 5.1.1 Geographic Atrophy (GA)
  3. 5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  4. 5.1.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  5. 5.1.4 Others
  6. 5.2 Global Complement Inhibitors Sales Volume by Application
  7. 5.2.1 Global Complement Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Complement Inhibitors Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Complement Inhibitors Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Complement Inhibitors Sales Value by Application
  11. 5.3.1 Global Complement Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Complement Inhibitors Sales Value by Application (2021-2032)
  13. 5.3.3 Global Complement Inhibitors Sales Value Share by Application (2021-2032)
6 Complement Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Complement Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Complement Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Complement Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Complement Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Complement Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Complement Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Complement Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Complement Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Complement Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Complement Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Complement Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Complement Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Complement Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Complement Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Complement Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Complement Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Complement Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Complement Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Complement Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Complement Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Complement Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Complement Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Complement Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Complement Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Complement Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Complement Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Complement Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Complement Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Complement Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Complement Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Complement Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Complement Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Complement Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Complement Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Complement Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Complement Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Complement Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Complement Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Complement Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Complement Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Complement Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Complement Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Complement Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Complement Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Complement Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Complement Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Complement Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Complement Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Complement Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Complement Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Complement Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Complement Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Complement Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Complement Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Complement Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Complement Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Complement Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Complement Inhibitors Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Complement Inhibitors Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Apellis Pharmaceuticals
  14. 8.3.1 Apellis Pharmaceuticals Company Information
  15. 8.3.2 Apellis Pharmaceuticals Business Overview
  16. 8.3.3 Apellis Pharmaceuticals Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Apellis Pharmaceuticals Complement Inhibitors Product Portfolio
  18. 8.3.5 Apellis Pharmaceuticals Recent Developments
  19. 8.4 Astellas Pharma
  20. 8.4.1 Astellas Pharma Company Information
  21. 8.4.2 Astellas Pharma Business Overview
  22. 8.4.3 Astellas Pharma Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Astellas Pharma Complement Inhibitors Product Portfolio
  24. 8.4.5 Astellas Pharma Recent Developments
  25. 8.5 CSL Behring
  26. 8.5.1 CSL Behring Company Information
  27. 8.5.2 CSL Behring Business Overview
  28. 8.5.3 CSL Behring Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CSL Behring Complement Inhibitors Product Portfolio
  30. 8.5.5 CSL Behring Recent Developments
  31. 8.6 Pharming Healthcare
  32. 8.6.1 Pharming Healthcare Company Information
  33. 8.6.2 Pharming Healthcare Business Overview
  34. 8.6.3 Pharming Healthcare Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pharming Healthcare Complement Inhibitors Product Portfolio
  36. 8.6.5 Pharming Healthcare Recent Developments
  37. 8.7 Regeneron Pharmaceuticals
  38. 8.7.1 Regeneron Pharmaceuticals Company Information
  39. 8.7.2 Regeneron Pharmaceuticals Business Overview
  40. 8.7.3 Regeneron Pharmaceuticals Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron Pharmaceuticals Complement Inhibitors Product Portfolio
  42. 8.7.5 Regeneron Pharmaceuticals Recent Developments
  43. 8.8 Samsung Bioepis
  44. 8.8.1 Samsung Bioepis Company Information
  45. 8.8.2 Samsung Bioepis Business Overview
  46. 8.8.3 Samsung Bioepis Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Samsung Bioepis Complement Inhibitors Product Portfolio
  48. 8.8.5 Samsung Bioepis Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 UCB Complement Inhibitors Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Roche Complement Inhibitors Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Complement Inhibitors Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Complement Inhibitors Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Takeda
  74. 8.13.1 Takeda Company Information
  75. 8.13.2 Takeda Business Overview
  76. 8.13.3 Takeda Complement Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Takeda Complement Inhibitors Product Portfolio
  78. 8.13.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Complement Inhibitors Value Chain Analysis
  2. 9.1.1 Complement Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Complement Inhibitors Sales Mode & Process
  6. 9.2 Complement Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Complement Inhibitors Distributors
  9. 9.2.3 Complement Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst